mRNA m5C Alteration in Azacitidine Demethylation Treatment of Acute Myeloid Leukemia
Open Access
- 17 December 2024
- journal article
- research article
- Published by Wiley in Molecular Carcinogenesis
- Vol. 64 (3) , 502-512
Abstract
The DNA demethylating therapy with azacitidine (AZA) is a promising therapeutic strategy for elderly patients with acute myeloid leukemia (AML). AZA primarily inhibits DNA methylation, promotes cell differentiation and apoptosis in AML. However, as a cytosine nucleoside analog, AZA also has the potential to be incorporated into RNA molecules. To assess the impact of AZA on RNA m5C methylation during demethylating therapy, we conducted Nanopore direct‐RNA sequencing on samples from three AML patients pre and after demethylating therapy, as well as on HL‐60 cells pretreated with AZA. We performed an integrated analysis of the transcriptome and the m5C methylome, contrasting the states of complete remission with those of active disease (AML). Our results revealed an extensive demethylation effect at the RNA level attributable to AZA and found that mRNA m5C modification may play a pivotal role in the progression of AML. Additionally, S100P was identified as a biomarker with significant prognostic implications. We also conducted a conjoint analysis of the transcriptome and the m5C methylome of the full‐length transcripts, uncovering several dysregulated mRNA isoforms. Collectively, our findings indicate that mRNA m5C methylation is implicated during AML progression, and AZA exhibits an overall suppressive effect on this process.Keywords
This publication has 34 references indexed in Scilit:
- Non‐m6A RNA modifications in haematological malignanciesClinical and Translational Medicine, 2024
- Comprehensive analysis of m 6 A methylome alterations after azacytidine plus venetoclax treatment for acute myeloid leukemia by nanopore sequencingComputational and Structural Biotechnology Journal, 2024
- NSUN2 promotes lung adenocarcinoma progression through stabilizing PIK3R2 mRNA in an m5C‐dependent mannerMolecular Carcinogenesis, 2024
- Comprehensive analysis of m6A methylome and transcriptome by Nanopore sequencing in clear cell renal carcinomaMolecular Carcinogenesis, 2024
- m5C regulator‐mediated methylation modification patterns and tumor microenvironment infiltration characteristics in acute myeloid leukemiaImmunity, Inflammation and Disease, 2024
- Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2023
- Role of RNA modifications in carcinogenesis and carcinogen damage responseMolecular Carcinogenesis, 2022
- The role of the HIF‐1α/ALYREF/PKM2 axis in glycolysis and tumorigenesis of bladder cancerCancer Communications, 2021
- S100P: a novel therapeutic target for cancerAmino Acids, 2010
- S100P is selectively upregulated in tumor cell lines challenged with DNA cross-linking agentsLeukemia Research, 2005